Clinical Trial

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated November 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-01-28; most recent amendment 2024-07-01.
Status change: Recruiting → Active, Not Recruiting 2024-07-01
Status change: Not Yet Recruiting → Recruiting 2022-01-29
Trial Details
NCT Number NCT05215470
Lead Sponsor Hospital das Clínicas de Ribeirão Preto
Collaborators: Bristol-Myers Squibb, Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions Renal Cancer Metastatic
Enrollment 100 participants
Start Date 2022-01-18
Primary Completion 2024-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-03